| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA443: Obeticholic acid for treating primary biliary cholangitis |
|
Medicine details |
|
| Medicine name | obeticholic acid (Ocaliva®) |
| Formulation | 5 mg, 10 mg tablet |
| Reference number | 2135 |
| Indication | Treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA |
| Company | Intercept Pharmaceuticals Inc |
| BNF chapter | Gastro-intestinal system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/11/2016 |
| NICE guidance | TA443: Obeticholic acid for treating primary biliary cholangitis |